Are Statins Worth the Side Effects? (TRT Q&As)
Timeline
Timestamp
Topic
00:40
Are statins worth the risk of side effects if my calcium score is rising?
The caller says his coronary calcium score rose from the 70s to 242 and is worried about statin side effects. Dr. O’Connor says the progression of coronary plaque makes aggressive risk reduction important and discusses low-dose rosuvastatin plus additional lipid-lowering therapy when needed.
The caller says his coronary calcium score rose from the 70s to 242 and is worried about statin side effects. Dr. O’Connor says the progression of coronary plaque makes aggressive risk reduction important and discusses low-dose rosuvastatin plus additional lipid-lowering therapy when needed.
13:40
Do my elevated liver and kidney numbers mean I need to see specialists?
The caller’s primary care doctor is concerned about mildly abnormal liver enzymes and creatinine. Dr. O’Connor explains that the liver enzyme pattern may reflect muscle spillover and that daily creatine can falsely elevate creatinine, especially when cystatin C is normal, and suggests repeating labs after stopping creatine before assuming kidney disease.
The caller’s primary care doctor is concerned about mildly abnormal liver enzymes and creatinine. Dr. O’Connor explains that the liver enzyme pattern may reflect muscle spillover and that daily creatine can falsely elevate creatinine, especially when cystatin C is normal, and suggests repeating labs after stopping creatine before assuming kidney disease.
31:30
How should I use HCG and enclomiphene to restore fertility after years on testosterone?
The caller stopped testosterone after seven years of use and asks about adding enclomiphene to high-dose HCG. Dr. O’Connor says testosterone needs to remain stopped for fertility recovery and discusses HCG with a SERM, emphasizing that spermatogenesis takes time and treatment may need to continue for several months.
The caller stopped testosterone after seven years of use and asks about adding enclomiphene to high-dose HCG. Dr. O’Connor says testosterone needs to remain stopped for fertility recovery and discusses HCG with a SERM, emphasizing that spermatogenesis takes time and treatment may need to continue for several months.
44:00
What should I watch for during my first few weeks on TRT?
The caller is two weeks into 100 mg of testosterone per week and has a history of anxiety. Dr. O’Connor says it is still early, advises giving the therapy time to reach steady state, monitoring how he feels, and waiting roughly six to eight weeks before relying heavily on follow-up hormone labs.
The caller is two weeks into 100 mg of testosterone per week and has a history of anxiety. Dr. O’Connor says it is still early, advises giving the therapy time to reach steady state, monitoring how he feels, and waiting roughly six to eight weeks before relying heavily on follow-up hormone labs.
52:55
What should I watch for during my first few weeks on TRT?
The caller is two weeks into 100 mg of testosterone per week and has a history of anxiety. Dr. O’Connor says it is still early, advises giving the therapy time to reach steady state, monitoring how he feels, and waiting roughly six to eight weeks before relying heavily on follow-up hormone labs.
The caller is two weeks into 100 mg of testosterone per week and has a history of anxiety. Dr. O’Connor says it is still early, advises giving the therapy time to reach steady state, monitoring how he feels, and waiting roughly six to eight weeks before relying heavily on follow-up hormone labs.
61:30
Can rosuvastatin interfere with testosterone or fertility treatment?
The caller asks whether rosuvastatin could interfere with his Clomid and HCG fertility regimen. Dr. O’Connor explains that statins can modestly reduce endogenous androgen production in some men, but he does not view that as a reason to stop needed cardiovascular treatment in this case.
The caller asks whether rosuvastatin could interfere with his Clomid and HCG fertility regimen. Dr. O’Connor explains that statins can modestly reduce endogenous androgen production in some men, but he does not view that as a reason to stop needed cardiovascular treatment in this case.
Video Summary
Andrew runs a clinician-led Q&A that prioritizes clear decision-making over shortcuts and trends. Early questions frame how symptoms, medical history, and baseline labs determine whether hormone therapy is appropriate. The episode repeatedly ties treatment choices to measurable endpoints and long-term safety.
A major segment focuses on fertility planning after prolonged testosterone use and the practical steps needed to assess recovery. The discussion contrasts home testing with formal semen analysis and highlights the importance of realistic timelines. hCG and clomiphene are presented as options to support endogenous signaling, with emphasis on monitoring objective results.
Later, the conversation widens to cardiometabolic prevention, especially LDL control and the consequences of untreated atherosclerotic risk. The hosts discuss statins and advanced lipid therapies as escalation tools when targets are not met. Blood pressure and metabolic support are treated as integral to a prevention plan aimed at reducing heart-attack risk.
Drug Callouts
Drug
Description
hCG
Human chorionic gonadotropin is a hormone used clinically to stimulate Leydig cell testosterone production and support spermatogenesis in select men. In the fertility discussion, it is presented as an adjunct when coming off TRT to help re-activate testicular function.
Clomid
Clomiphene citrate is a selective estrogen receptor modulator that increases gonadotropin signaling by reducing estrogen feedback at the hypothalamus. It is discussed as a way to raise endogenous testosterone and potentially improve fertility parameters, with attention to mixed response in semen results.
Rosuvastatin
Rosuvastatin is a high-intensity HMG‑CoA reductase inhibitor that lowers LDL cholesterol and reduces cardiovascular event risk. The panel references it while weighing how aggressively to treat lipids in high-risk patients.
Atorvastatin
Atorvastatin is an HMG‑CoA reductase inhibitor commonly used to lower LDL cholesterol and stabilize atherosclerotic plaque. It is mentioned as part of real-world statin selection when cholesterol goals are not met.
Repatha
Evolocumab (Repatha) is a PCSK9 inhibitor that markedly lowers LDL cholesterol by increasing hepatic LDL receptor recycling. In the lipid section, it comes up as a next-step option when statins alone do not achieve adequate risk reduction.
Praluent
Alirocumab (Praluent) is a PCSK9 inhibitor used to lower LDL cholesterol in patients with high cardiovascular risk or familial hypercholesterolemia. It is discussed alongside other advanced therapies as an escalation pathway for difficult lipid profiles.
Vascepa
Icosapent ethyl (Vascepa) is a purified EPA omega‑3 product indicated to reduce cardiovascular risk in certain patients with elevated triglycerides on statin therapy. The episode cites it in the context of comprehensive cardiometabolic prevention beyond LDL alone.
Metformin
Metformin is an insulin-sensitizing biguanide used for type 2 diabetes and metabolic syndrome, improving glycemic control primarily by reducing hepatic glucose production. It is brought up as part of a broader prevention plan when glucose control intersects with cardiovascular risk.
Condition Callouts
Condition
Description
Atherosclerosis
Atherosclerosis is a chronic inflammatory disease in which cholesterol-rich plaque builds within arterial walls and narrows blood flow. It is referenced as the underlying process that makes LDL reduction clinically meaningful.
Hypertension
Hypertension is persistently elevated arterial blood pressure that increases the risk of stroke, heart failure, kidney disease, and myocardial infarction. The episode treats blood pressure control as a non-negotiable companion to hormone and lipid optimization.
Obesity
Obesity is excess adiposity that disrupts metabolic and hormonal signaling and raises cardiometabolic risk. It is mentioned while discussing population-level trends that correlate with worsening male reproductive and cardiovascular outcomes.
Myocardial infarction
Myocardial infarction is acute heart muscle injury due to prolonged ischemia, most commonly from coronary plaque rupture and thrombosis. Heart attacks are repeatedly used as the concrete outcome that prevention strategies are designed to avoid.
Key Takeaways
- Fertility planning after TRT should start with formal semen analysis and a realistic timeline for recovery rather than relying on home screening kits.
- When discontinuing testosterone for conception, therapies that stimulate gonadotropin signaling can be considered, but response should be measured with repeat labs and semen parameters.
- Lipid management is treated as primary prevention, and LDL lowering intensity is matched to overall atherosclerotic risk, not subjective wellness.
- Advanced agents such as PCSK9 inhibitors and EPA therapy are framed as add-ons when conventional statins do not achieve acceptable risk reduction.
- A durable optimization plan integrates hormones with blood pressure and metabolic control to reduce heart-attack risk over decades.